Ceribell Posts 36% Revenue Growth in 2025, Expands FDA Clearances — CeriBell, Inc.

Event summary

Ceribell reported $89.1 million in total revenue for 2025, up 36% YoY, with Q4 revenue at $24.8 million, a 34% increase.
The company ended 2025 with 647 active accounts and maintained an 88% gross margin.
Ceribell secured FDA 510(k) clearances for its delirium monitoring solution and expanded its Clarity algorithm to neonates.
Net loss for 2025 widened to $53.4 million, though improved from $40.5 million in 2024.
Ceribell projects 2026 revenue of $111–$115 million, a 25–29% growth.

The big picture

Ceribell's 2025 performance highlights its strategic focus on expanding its EEG platform's applications, particularly in high-growth areas like neonatal and pediatric care. The company's ability to maintain high gross margins while increasing revenue suggests strong market demand, but its widening net loss signals ongoing investment in commercial scaling. The $1.5 billion market opportunity cited by CEO Jane Chao underscores the potential for further growth, contingent on execution and regulatory momentum.

What we're watching

Market Penetration: Whether Ceribell can sustain its 36% revenue growth amid increasing competition in neurological diagnostics.
Regulatory Advantage: How the expanded FDA clearances will accelerate adoption in pediatric and neonatal care.
Operational Efficiency: The pace at which Ceribell can reduce its net loss while scaling its commercial organization.